on OXURION (EBR:OXUR)
Oxurion completes partial acquisition of Axiodis CRO
Oxurion NV, a biopharmaceutical company based in Leuven, has secured financing to acquire a 72% stake in Axiodis CRO. This financing, obtained from Atlas Special Opportunities, follows a rigorous due diligence process. Closing of this transaction is expected on August 1, 2025. The dilution table is available on the company's website.
This acquisition is part of Oxurion's strategy to create an integrated clinical data platform to support therapeutic development. Axiodis' expertise is seen as a key asset for Oxurion's development as a strategic partner in clinical research.
Oxurion also plans to identify other targets in France and Europe to strengthen a division dedicated to clinical data.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news